丁福明 1-butylbiguanide CAS#:692-13-7

您好！欢迎来到化工e站网登陆注册

产品字典

氯化钾 | 乙二醇 | 碘甲烷 | 溴化亚铜 | 叔丁醇钾 | DMAP

结构式搜索

首页化工产品目录原料药激素及调节内分泌功能类药胰腺激素及其它调节血糖药丁福明

丁福明

产品纠错

CAS号：692-13-7 | 英文名称：1-butylbiguanide

分子式 C₆H₁₅N₅

分子量 157

EINECS号 2117264

MDL MFCD00242653

Smiles C(=N)(NCCCC)NC(=N)N

InChIKey XSEUMFJMFFMCIU-UHFFFAOYSA-N

乙二醇化学百科

基本信息

中文名称	丁福明
英文名称	1-butylbiguanide
CAS号	692-13-7
分子式	C6H15N5
分子量	157.2168
EINECS号	2117264

物化性质

熔点	174-176 °C
沸点	271.89°C (rough estimate)
密度	1.0291 (rough estimate)
折射率	1.8070 (estimate)
酸度系数(pKa)	12.27±0.10(Predicted)

安全信息

生产及用途

生物活性

Buformin (1-Butylbiguanide) 是一种有效的 AMPK 活化剂，也是具有口服活性的双胍类降血糖试剂 (antidiabetic agent)。Buformin 降低肝糖异生并降低血糖生成。Buformin 也具有抗癌活性，可以应用于癌症研究，如宫颈癌、乳腺癌等。

体外研究

Buformin (0-10 mM; 5 days) inhibits SKBR3 and BT474 cells growth as a concentration-dependent manner, exhibits IC ₅₀ values of 246.7 μM and 98.6 μM for erbB-2-overexpressing SKBR3 and BT474 cells, respectively.Buformin (0-3 mM; 48 hours) increases the percentage of cells in G0/G1 phase and reduced the percentage of cells in S phase, especially in the SKBR3 cells.Buformin (0-3 mM; 24 hours) suppresses RTK activation, including erbB-2 and IGF1R signaling downstream, and Akt activation/phosphorylation is inhibited in both SKBR3 and BT474 cells.

Cell Viability Assay

Cell Line:	ErbB-2-overexpressing SKBR3 and BT474 cells
Concentration:	0 μM, 1 μM, 3 μM, 10 μM, 30 μM, 100 μM, 300 μM, 1, 3, or 10 mM
Incubation Time:	5 days
Result:	Reduced cell viability in erbB-2-overexpressing breast cells.

Cell Cycle Analysis

Cell Line:	ErbB-2-overexpressing SKBR3 and BT474 cells
Concentration:	0.5 mM; 1 mM; 3 mM
Incubation Time:	48 hours
Result:	Increased cells arresting in G0/G1 phase.

Western Blot Analysis

Cell Line:	ErbB-2-overexpressing SKBR3 and BT474 cells
Concentration:	0 mM, 0.1 mM, 0.3 mM, 1 mM, or 3 mM
Incubation Time:	24 hours
Result:	Decreased p-AMPK, p-p706S, p-ERK1/2 expression in a concentration-dependent manner.

体内研究

Buformin (oral administation; 7.6 mmol/kg of chow; 7 days) exhibits significantly reduced tumor volumes and weights, and hinders mammary morphogenesis and proliferation in MMTV-erbB-2 transgenic mice

Animal Model:	Female MMTV-erbB-2 transgenic mice
Dosage:	7.6 mmol/kg
Administration:	Oral administation; 7 days
Result:	Inhibited mammary syngeneic tumor growth in MMTV-erbB-2 transgenic mice.